These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The in vitro and in vivo effects of adenovirus-mediated inhibitor of growth 4 and interleukin-24 co-expression on the radiosensitivity of human lung adenocarcinoma].
    Author: Huang JH, Ling CH, Yang JC, Zhao DG, Xie YF, Sheng WH.
    Journal: Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jun; 34(6):413-8. PubMed ID: 21781511.
    Abstract:
    OBJECTIVE: To study the radiosensitivity of the recombinant adenoviral vector (called Ad-ING4-IL-24) carrying and co-expressing inhibitor of growth 4 (ING4) and interleukin-24 (IL-24) to human lung adenocarcinoma and the underlying mechanisms. METHODS: The expression levels of ING4 and IL-24 were detected by Western blot. The growth-suppressing and apoptosis-inducing effect of Ad-ING4-IL-24 combined with radiotherapy on SPC-A-1 lung carcinoma cells were assessed by MTT assay and FCM respectively. The 25 nude mice were randomly divided into 5 groups of 5 mice ecah: PBS group, Ad group, Ad-ING4-IL-24 group, radiotherapy group and joint group (Ad-ING4-IL-24 combined radiotherapy). Mice in all groups except radiotherapy group were intratumorally injected every other day for 6 cycles. The short and long axes of the tumor were measured dynamically, tumor volume was calculated as: V = L × W(2/2), changes in tumor volume were graphed. The human lung carcinoma model was established with SPC-A-1 cells in nude mice. The ratios of tumor-suppression and q were calculated. The expression of Caspase-3, Bcl-2, Bax, VEGF in tumor samples were detected by immunohistochemistry. RESULTS: The expressions of ING4 and IL-24 were successfully expressed in SPC-A-1 cells. MTT assay and FCM showed that the levels of cell-growth inhibition and apoptosis induction in Ad-ING4-IL-24 combined with radiotherapy group [(86.2 ± 0.8)%, (60.9 ± 1.0)%] were higher than in Ad-ING4-IL-24 group [(49.8 ± 0.3)%, (26.3 ± 1.3)%] and in radiotherapy group [(44.4 ± 2.2)%, (33.3 ± 0.8)%] (ratio of cell-growth inhibition, F = 550.88, P < 0.01; ratio of induced apoptosis F = 614.08, P < 0.01). Ad-ING4-IL-24 combined with radiotherapy showed an enhanced radiosensitivity effect on human lung adenocarcinoma (q = 1.20). In Ad-ING4-IL-24 group, radiotherapy group and Ad-ING4-IL-24 combined with radiotherapy group, the weight inhibition ratio was 49.5% (5 nude mice), 35.4% (5 nude mice), 79.8% (5 nude mice) respectively. Ad-ING4-IL-24 combined with radiotherapy had a synergetic and enhanced radiosensitivity effect on inhibiting the growth of transplanted tumor (q = 1.18). According to immunohistochemistry, Ad-ING4-IL-24 was shown to up-regulate the expression of Bax and Caspase-3 but down-regulate the expression of Bcl-2 and VEGF. CONCLUSION: Ad-ING4-IL-24 had an enhanced radiosensitivity effect on human lung adenocarcinoma, and therefore acted as a radiotherapy sensitizer, which may be related to its effect on apoptosis-induction and antiangiogenesis.
    [Abstract] [Full Text] [Related] [New Search]